N-[2-(pyridin-3-yl)-1,3-benzoxazol-5-yl]-2H-1,3-benzodioxole-5-carboxamide

• 分子结构分类: 有机化合物 - 有机杂环化合物 - 苯并恶唑类
• 英文名称: N-[2-(pyridin-3-yl)-1,3-benzoxazol-5-yl]-2H-1,3-benzodioxole-5-carboxamide
• 英文别名: N-(2-pyridin-3-yl-1,3-benzoxazol-5-yl)-1,3-benzodioxole-5-carboxamide
• 化学式: C₂₀H₁₃N₃O₄
• 分子量: 359.341
• InChiKey: KJGHWYJJBAHACU-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  3
• 重原子数：
  27
• 可旋转键数：
  3
• 环数：
  5.0
• sp3杂化的碳原子比例：
  0.05
• 拓扑面积：
  86.5
• 氢给体数：
  1
• 氢受体数：
  6

文献信息

• [EN] PROBES FOR IMAGING HUNTINGTIN PROTEIN<br/>[FR] SONDES D'IMAGERIE DE LA PROTÉINE HUNTINGTINE
  申请人：CHDI FOUNDATION INC

  公开号：WO2016033445A1

  公开（公告）日：2016-03-03

  Provided are imaging agents comprising a compound of Formula (I), or a pharmaceutically acceptable salt thereof, and methods of their use.

  提供了包含化合物I式或其药用可接受盐的成像试剂，以及它们的使用方法。
• Probes for imaging huntingtin protein
  申请人：CHDI Foundation, Inc.

  公开号：US10479802B2

  公开（公告）日：2019-11-19

  Provided are imaging agents comprising a compound of Formula (I), or a pharmaceutically acceptable salt thereof, and methods of their use.

  本文提供了由式（I）化合物或其药学上可接受的盐组成的成像剂及其使用方法。
• Compounds for targeting mutant huntingtin protein and uses thereof
  申请人：CHDI Foundation, Inc.

  公开号：US11389438B2

  公开（公告）日：2022-07-19

  The present disclosure relates generally to compounds that simultaneously bind both mutant huntingtin protein (mHTT) and an ubiquitin E3 ligase and their use as therapeutic agents, for example, in treating diseases, such as neurodegenerative disorders caused by aggregation of mHTT.

  本公开总体上涉及同时结合突变亨廷汀蛋白（mHTT）和泛素 E3 连接酶的化合物及其作为治疗剂的用途，例如，用于治疗疾病，如由 mHTT 聚合引起的神经退行性疾病。
• PROBES FOR IMAGING HUNTINGTIN PROTEIN
  申请人：CHDI Foundation, Inc.

  公开号：EP3186233A1

  公开（公告）日：2017-07-05
• COMPOUNDS FOR TARGETING MUTANT HUNTINGTIN PROTEIN AND USES THEREOF
  申请人：CHDI Foundation, Inc.

  公开号：US20200276176A1

  公开（公告）日：2020-09-03

  The present disclosure relates generally to compounds that simultaneously bind both mutant huntingtin protein (mHTT) and an ubiquitin E3 ligase and their use as therapeutic agents, for example, in treating diseases, such as neurodegenerative disorders caused by aggregation of mHTT.